The Discounted Cash Flow (DCF) valuation of Akebia Therapeutics Inc (AKBA) is 2.11 USD. With the latest stock price at 1.40 USD, the upside of Akebia Therapeutics Inc based on DCF is 50.4%.
Based on the latest price of 1.40 USD and our DCF valuation, Akebia Therapeutics Inc (AKBA) is a buy. buying AKBA stocks now will result in a potential gain of 50.4%.
| Range | Selected | |
| WACC / Discount Rate | 7.0% - 9.9% | 8.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 1.39 - 4.56 | 2.11 |
| Upside | -0.7% - 225.4% | 50.4% |